deltatrials
Terminated PHASE1 INTERVENTIONAL 1-arm NCT01268644

Effects of Metreleptin in Type 1 Diabetes Mellitus

Open Label Single Center Pilot Study to Study Teh Effects of Metreleptin Administration in Patients With Type 1 Diabetes Mellitus ( T1DM ).

Sponsor: Amylin Pharmaceuticals, LLC.

Conditions Type 1 Diabetes
Interventions Leptin
Updated 9 times since 2017 Last updated: Jul 17, 2019 Started: Sep 30, 2010 Primary completion: Jan 31, 2013 Completion: Aug 31, 2014
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Sponsor request

Other terminated trials from Amylin Pharmaceuticals, LLC.

More terminations from Amylin Pharmaceuticals, LLC.

Other Type 1 Diabetes trials with similar outcome

Browse all Type 1 Diabetes trials

A PHASE1 clinical study on Type 1 Diabetes, this trial is terminated or withdrawn. The trial is conducted by Amylin Pharmaceuticals, LLC. and has accumulated 9 data snapshots since 2010. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotTerminated~Feb 2017 – ~Jun 2018 · 16 months · monthly snapshotTerminated~Jun 2018 – ~Sep 2019 · 15 months · monthly snapshotTerminated~Sep 2019 – ~Jan 2021 · 16 months · monthly snapshotTerminated~Jan 2021 – ~Dec 2022 · 23 months · monthly snapshotTerminated~Dec 2022 – ~Jan 2023 · 31 days · monthly snapshotTerminated~Jan 2023 – ~Jul 2024 · 18 months · monthly snapshotTerminated~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotTerminated~Sep 2024 – present · 24 months · monthly snapshotTerminated

Change History

9 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE1

  3. Jan 2023 — Jul 2024 [monthly]

    Terminated PHASE1

  4. Dec 2022 — Jan 2023 [monthly]

    Terminated PHASE1

  5. Jan 2021 — Dec 2022 [monthly]

    Terminated PHASE1

▶ Show 4 earlier versions

  1. Sep 2019 — Jan 2021 [monthly]

    Terminated PHASE1

  2. Jun 2018 — Sep 2019 [monthly]

    Terminated PHASE1

  3. Feb 2017 — Jun 2018 [monthly]

    Terminated PHASE1

  4. Jan 2017 — Feb 2017 [monthly]

    Terminated PHASE1

    First recorded

Sep 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Amylin Pharmaceuticals, LLC.
  • Juvenile Diabetes Research Foundation
  • University of Texas Southwestern Medical Center
Data source: University of Texas Southwestern Medical Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations